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ABSTRACT
Objective: The purpose of this study was to compare the clinical efficacy and safety of cefmetazole
given by IV push with that of parenterally administered cefoxitin for the treatment of endometritis
following cesarean delivery.
Methods: In a single-blind, multicenter, prospective, randomized study, 355 patients with endo-
metritis after cesarean delivery were enrolled and received medication. Administered was either
cefmetazole sodium, 2 g by IV push over I min q 8 h, or cefoxitin sodium, 2 g IV q 6 h in a 2:1 ratio.
The patients were followed for clinical responses and side effects.
Results: The cure rate for cefmetazole was 89% and for cefoxitin it was 79% (P 0.006). The
adverse events were similar in both groups.
Conclusions: Cefmetazole was significantly more effective than cefoxitin in the treatment of
endometritis following cesarean delivery. (C) 1995 Wiley-Liss, Inc.
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major cause of maternal morbidity during the
postpartum period is endometritis. Cesarean
delivery is the most important clinical factor for the
development of endometritis. The incidence of en-
dometritis following cesarean delivery has ranged
from 5 to 85%. Endometritis is polymicrobial
2-4
in nature; therefore, antibiotic coverage often re-
quires multiple agents to achieve adequate cover-
age. In an attempt to simplify the therapy, some
investigatorss’6 have evaluated monotherapy with
cephamycins.
Cephamycins are a group of parenterally admin-
istered cephalosporins characterized by an alpha-
methoxy group at position 7. This configuration
enables the cephamycins to be effective against a
remarkable number of aerobic and anaerobic bacte-
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ria. Studies comparing different cephamycins for
prophylaxis and therapy have yielded similar effi-
7--9 cacy and cure rates.
With most regimens reporting similar cure rates
for different cephamycins, the focus has shifted to
the cost and ease of administration. A drug with a
longer half-life requiring less frequent adminis-
tration can result in considerable savings. 1’1
Cefmetazole, a new cephamycin, has a longer half-
life than cefoxitin. It has also been demonstrated to
be more active than cefoxitin against isolated spe-
cies.
2-14
With this in mind, we initiated this random-
ized, controlled trial to compare the clinical effec-
tiveness and safety of cefmetazole vs. cefoxitin in
the treatment of endometritis after cesarean de-
livery.
MATERIALS AND METHODS
Patients
The patients eligible for enrollment were hospital-
ized women, 16 years of age or older, with a pre-
sumptive diagnosis of endometritis after cesarean
delivery. The diagnosis of endometritis was made
by the clinical findings of temperature >38.3C
during the 1st 24 h after surgery or >38C after
the 1st 24-h period, fundal tenderness, adnexal
tenderness, and purulent lochia. All findings were
required for the enrollment of a patient in this
study. Patients with symptoms suggesting other
loci of infection, e.g., urinary tract or pulmonary
system, were excluded from the study, as were
patients who had received antibiotics, excluding
antibiotic prophylaxis, within 48 h of recruitment
in the study. Also excluded were patients with a
history of hypersensitivity to penicillin or cephalo-
sporins/cephamycins, neutropenia, liver or kidney
dysfunction, or prior enrollment in this study.
Study Design
The clinical protocol for this study was approved
by the institutional review boards of the 12 partici-
pating centers. The centers were chosen from geo-
graphic areas so as to obtain a heterogeneous group
of patients. A simple computer-generated random-
ization table was provided by the Upjohn Company
for each site. A 2:1 allocation to cefmetazole vs.
cefoxitin was used. Assuming that cefoxitin has a
95% cure rate, to detect a 5% difference with an
80% power, we needed approximately 3 50 cefmeta-
zole subjects and 175 cefoxitin subjects. However,
enrolling this number of patients was beyond the
resources available for this investigation.
After each patient had given written informed
consent, a physical examination was performed and
the following laboratory studies were conducted:
urinalysis, CBC with differential, prothrombin
time, direct Coomb’s test, alanine aminotransferase,
aspartate aminotransferase, lactic dehydrogenase,
alkaline phosphatase, total bilirubin, blood urea
nitrogen, and serum creatinine. Cultures were ob-
tained from the urine, uterus, and, if indicated,
blood prior to treatment. The indications for blood
culture were left to the discretion of each individual
investigator. Uterine cultures were obtained by
transcervical protected brush or endometrial aspi-
ration curette. Cultures were obtained for faculta-
tive aerobes and anaerobes. For facultative aerobes,
port-a-cul medium was inoculated onto sheep blood
agar plates, MacConkey agar plates, chocolate agar
plates, Martin-Lewis agar plates, and V-agar plates.
For anaerobes, the medium was inoculated onto
CDC anaerobic blood agar, CDC anaerobic laked
blood agar with kanamycin and vancomycin, and
prereduced PRAS brain heart infusion. The bacte-
ria were isolated and identified, and their suscepti-
bility to testing was determined by a serial agar
dilution or by Kirby-Bauer disk diffusion.
Cefmetazole or cefoxitin was administered IV at
a dosage of 2 g over min q 8 h or 2 g by 30-min
infusion q 6 h, respectively. A quick IV bolus route
was chosen for cefmetazole to see if it was tolerated
without an increase in local side effects. The study
medication was continued for 24 h following the
resolution of the signs and symptoms of endometri-
tis. No discharge antibiotics were given to either
group.
Patient Evaluation
Over the course of treatment, which lasted 1-18
days, the patients were observed regarding their
clinical status and potential adverse reactions. Spe-
cific questions were asked daily regarding any local
discomfort at the IV site. Other factors included
oral temperature evaluations every 4-6 h. The
blood culture was repeated daily for a patient with a
positive culture before treatment until it became
negative. All clinical laboratory tests were repeated
every 3 days while the patient was hospitalized and
on the day of discharge. The uterine cultures were
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repeated only if a patient required a change in
antibiotics.
A satisfactory clinical response to treatment was
defined by the disappearance of any signs or symp-
toms of endometritis until the follow-up visit at
3-4 weeks. A clinical failure was defined as a tem-
perature of >38C on one or more occasions in a
patient who had received the study medication for a
minimum of 48 h, along with persistence or wors-
ening of the signs and symptoms of endometritis
that required changing the antimicrobial agents.
Statistical Evaluation
For the demographic variables of a continuous na-
ture, e.g., age, the treatment differences were tested
using a 1-way analysis of variance (ANOVA)
model, with treatment as the factor. Categorical
demographic variables, e.g., race, and the propor-
tion of patients reporting at least medical event
during the study were compared between groups
using the Pearson chi-squared test for homogeneity
of distribution. The number of days in the hospital
until discharge was investigated using a 2-way
ANOVA, with treatment, investigator, and inves-
tigator-by-treatment interaction as factors and in-
vestigators with < 5 patients in either group pooled
together. The Beslow-day test was used to check for
investigator-by-treatment interaction for the pri-
mary efficacy variable. If the investigator-by-treat-
ment interaction was not significant (using a more
liberal value ofP > 0.10), then the Cochran-Man-
tel-Haenszel test was used to determine the treat-
ment effect. If the investigator-by-treatment inter-
action was significant (P< 0.10), then the
investigators were not pooled and a chi-squared test
was used to determine the treatment effect for each
investigator (P < 0.1 was used for testing the in-
vestigator-by-treatment interaction to reduce the
number of false positives, i.e., declaring that no
interaction is present). The evaluability rate was
compared between treatment groups using the
Cochran-Mantel-Haenszel test, as described above.
All statistical tests were 2-sided tests. Unless specif-
ically noted, the results were reported as statistically
significant ifP < 0.05 was obtained.
RESULTS
Patients
Among the 12 participating institutions, a total of
382 patients were enrolled: 252 in the cefmetazole
TABLE I. Patient characteristics: Evaluable patients
Variable Cefmetazole Cefoxitin
Mean age -+ SD (years) 24.3 5.6 24.3 +_ 5.5
Weight _+ SD (Kg) 78.3 18.2 78.0 +- 18.4
Height _+ SD (cm) 159.6 -+ 12.5 160.9 _+ 7.4
Race (%)
White 16.8 18.7
Black 41.0 46.3
Oriental 0.9 0
Hispanic 40.0 31.7
Others 1.3 3.3
Initial temperature +- SD (C) 38.2 0.7 38.2 0.7
group and 130 in the cefoxitin group. Of the 382
randomized patients, the 377 who received medi-
cation (248 received cefmetazole and 129 received
cefoxitin) were evaluable for safety. The initial pro-
tocol called for the enrollment of patients with any
pelvic infection, but this was soon restricted to
endometritis after cesarean delivery. Therefore, 22
patients without the aforementioned condition were
excluded for the efficacy evaluation (16 in the
cefmetazole group and 6 in the cefoxitin group).
Thus, there were 355 patients available with en-
dometritis for the efficacy evaluation (232 for
cefmetazole and 123 for cefoxitin). The evaluabil-
ity rate was not significantly different between treat-
ment groups. The 2 groups were comparable with
regard to age, weight, height, race, and initial
temperature (Table 1).
Outcome
The number of days in the hospital ranged from
to 18. The overall means for the treatment groups
were 5 days for the cefmetazole group and 5.4 days
for the cefoxitin group (P > 0.05). There was a
tendency for a longer hospital stay in the cefoxitin
group. The number ofdays required in the hospital
was comparable between treatment groups for in-
vestigators A.C., D.A.G., and M.M. However,
the average hospital stay was significantly higher in
the cefoxitin group (8.3 days) than in the cefmeta-
zole group (5.5 days; P 0.006) for the other
investigators pooled together. Most patients (74%)
defervesced within 1-3 days; the difference be-
tween treatment groups in days to defervescence
was not significantly different.
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TABLE 2. Clinical success rate: Evaluable patients
Cefmetazole Cefoxitin
N % N % P
Success 206 89 97 79
Failure 26 26 21
Total 232 100 123 100
0.006
The overall success rate for the cefmetazole
group was 206/232 (89%) compared with 97/123
(79%) for the cefoxitin group (P 0.006; Ta-
ble 2).
Initial cultures were available from 237 patients
(Table 3). An MIC of >64 Ixg/ml was considered
resistant. In general, the MIC for cefmetazole was
comparable with that of cefoxitin.
The overall frequency of adverse events was not
significantly different between the 2 groups; 24%
of patients in the cefmetazole group had or more
medical events compared with 23% of those treated
with cefoxitin. Medical events relating to the gas-
trointestinal system were the most frequent, with
13/248 (5.3%) patients reported for cefmetazole
and 10/129 (7.7%) for cefoxitin. Medication injec-
tion-site discomfort was reported in 12/248 (4.8%)
patients in the cefmetazole group and 5/129 (3.9%)
patients in the cefoxitin group. Allergic-type skin
reactions were seen in 6/248 (2.4%) of those given
cefmetazole, compared with 4/129 (3.1%) of those
in the cefoxitin series. The frequency of adverse
events was comparable among the investigators.
Failures
Twenty-six failures were reported in the cefmeta-
zole group and 26 in the cefoxitin group. The 23
patients in the cefmetazole group who continued to
have fever spikes and evidence of uterine infection
were deemed treatment failures. They subsequently
responded to alternate antibiotic regimens, which
included various combinations ofclindamycin, gen-
tamicin, ampicillin, cephalexin, doxycycline, and
amoxicillin/calvulanate. One patient developed sep-
tic thrombophlebitis and recovered after heparin
therapy. Two patients developed wound infections
and required alternate antibiotics. In the cefoxitin
group, 20 patients were deemed treatment failures
and were subsequently treated with different anti-
biotics. One patient developed a wound infection
and 2 patients were treated for presumed septic
thrombophlebitis with heparin. One patient re-
moved herself from the study because of a local
reaction. In addition, 2 patients had satisfactory
responses to the initial protocol treatment but had
relapses requiring additional antibiotics week af-
ter discharge.
DISCUSSION
The introduction of cephamycin antibiotics has al-
lowed monotherapy of various obstetric and gyne-
cologic infections. Monotherapy has many advan-
tages. First, and most important to the patient and
physician, is the fact that combination therapy in-
volves the possible toxic effects of 2 or more drugs.
Furthermore, there is an ease of administration
with monotherapy. It can be less expensive because
of the savings of not mixing antibiotics and using
fewer IV tubins. In the era of health care moving to
managed care, less expensive therapy does not go
unnoticed by health-care insurance administrators.
Cefoxitin was the 1st cephamycin agent intro-
duced and has been the most widely used. Clinical
cure rates with cefoxitin have ranged from 84 to
97%. 5’1s However, the major disadvantage of cef-
oxitin is its pharmacokinetics. The half-life of cef-
oxitin has been reported to be 30-60 min, 16’7
requiring administration q 6 h. Less frequent ad-
ministration is desirable because it is cheaper and
less time-consuming for pharmacy and nursing per-
sonnel.
Cefmetazole is a new cephamycin with the ad-
vantage of a longer half-life, 90 min, v’ allowing
administration q 8-12 h.
19 The replacement of a
cephamycin with less frequent dosing can result in
a 35% savings in the annual cost of antibiotics.
0,1
In addition, cefmetazole is significantly more stable
than cefoxitin with essentially no hydrolysis over
the 24-h incubation period,
g It has been shown
that, because of this longer half-life and more sta-
bility, the tissue level ofcefmetazole is significantly
higher than that of cefoxitin.
2 Concentrations of
cefmetazole persist longer in serum and tissue than
those of cefoxitin do, suggesting an advantage
for the treatment of endometritis. Even though
cefmetazole and cefoxitin have similar in vitro mi-
crobiology, the pharmacokinetic differences give
superiority to cefmetazole.
We have shown that endometritis after cesarean
delivery can be effectively treated with cefmetazole
therapy, achieving a clinical success rate of 89%,
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TABLE 3. Cefmetazole and Cefoxitin MIC
No. of MIC range
Organisms isolates (lg/ml)
Cefmetazole Cefoxitin
MIC range
% Susceptible (lg/ml) % Susceptible
Gram-positive aerobes
Enterococcus species 93 32-512
Streptococcus
Group B streptococci 62 0.25-32
Other species 28 0.125-64
Alpha hemolytic streptococci 19 0.5-32
Staphylococcus
Staph. epidermidis 42 0.5-32
Staph.-coagulase negative 21 I-16
Corynebacterium species 0.125-8
Gram-negative aerobes
Escherichia coli 38 0.25-4
Enterobacter species 18 8-512
Klebsiella pneumoniae 15 0.25-4
Proteus species 13 0.5-4
Pseudomonas 10 64-512
Neisseria gonorrhoeae 9 0.5-8
Acinetobacter species 9 32-512
Anaerobes
Bacteroides
B. bivius 47 0.25-64
B. fragilis 18 0.5-16
B. melaninogenicus 16 O. 12-8
Other species
Peptostreptococcus species 45 0.5-32
Clostridium species 5 0.25-16
Fusobacterium 4 0.5-8
Gardnerella vaginalis 13 0.125-0.5
<1 32-512 <1
I00 0.5-4.0 I00
96 0.5-64 93
100 2-16 100
100 0.125-32 100
100 1-32 100
100 0.125-16 100
100 I-16 100
12.5 16-512 12.5
I00 0.5-8 I00
O0 I-4 O0
0 64-512 0
I00 0.5-2 I00
<1 32-512 <1
94 0.25-64 94
100 I-16 100
I00 0.25-8 I00
95 0.125-32 95
100 1-64 80
O0 0.5-8 I00
100 0.5-2 100
and 79% for cefoxitin (P 0.006). Cemetazole is
more effective than cefoxitin because of the previ-
ously mentioned differences in pharmacokinetics.
Cefmetazole was given by IV bolus infusion rather
than by constant infusion over a period of time.
The highest serum and tissue levels of antibiotics
are reached by the bolus injection.
16,22 The admin-
istration of cefmetazole by 1-min IV push was not
associated with any increase in local reactions. This
finding is particularly attractive as it eliminates the
cost of infusion bags.
Even though the clinical cure rates were signifi-
cantly different between the groups, the time to
defervescence was not statistically different in the 2
groups. The reasons for this outcome are not clear.
In summary, in the evaluation ofan antibiotic in
this cost-containment era, the cost effectiveness of
treatment, including the economic impact of mak-
ing such changes, must be considered. This evalu-
ation can be simplified by assigning weights to
major criteria, i.e., spectrum of activity, pharma-
cokinetics, frequency and ease of administration,
adverse reactions, costs, and stability. Under this
analysis, cefmetazole received a much higher score
than cefoxitin did.
23
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